Search the Newsreel

Champions Oncology reports record $59.4M revenue, positive adjusted EBITDA for FY2026

Champions Oncology (CSBR) reported record fiscal year 2026 revenue of $59.4 million and positive adjusted EBITDA of $1.6 million for the full year. Despite these gains, the company posted a net loss due to continued investments in radiopharmaceuticals, its data platform, and commercial expansion. …

BlackRock (CRDF holder) discloses 863,259 Cardiff Oncology shares in 13G/A

BlackRock, Inc. has filed an amended Schedule 13G/A, reporting beneficial ownership of 863,259 shares of Cardiff Oncology, Inc. common stock, which represents a 1.3% stake in the company. BlackRock exercises sole voting and dispositive power over these shares, and the filing clarifies that no …

BlackRock (NYSE: BLK) reports 5.4% passive stake in ALX Oncology (ALXO)

BlackRock, Inc. has filed a Schedule 13G, disclosing a passive ownership of 5.4% in ALX Oncology Holdings Inc. This stake amounts to 7,327,850 common shares, with BlackRock exercising sole voting power over 7,231,560 shares and sole dispositive power over all beneficially owned shares. The …

At fiscal year-end, Champions Oncology had $4.9M cash, no debt

Champions Oncology (CSBR) reported record fiscal 2026 revenue of $59.4 million, up 4% year-over-year, despite missing prior-year data license revenue. The company ended the fiscal year with $4.9 million in cash and no debt, while achieving positive Adjusted EBITDA in all four quarters. Operating …

CGON (CGON) filer discloses 50,000-share sale plan and recent stock sales

An affiliate of CG Oncology (CGON), Ambaw Bellete, has filed a notice to sell 50,000 shares of common stock, valued at $3,627,995.00, through a stock option exercise on July 27, 2026. The filing also reports prior sales by the same individual, including 50,000 shares …

H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40

H.C. Wainwright has reiterated its Buy rating for Kura Oncology (KURA.US), maintaining a target price of $40. This suggests a continued positive outlook on the company's stock performance.

ALX Oncology Holdings Inc (ALXO) Cash Flow

This article provides a detailed cash flow statement for ALX Oncology Holdings Inc (ALXO), covering quarterly and annual data with year-over-year changes across operating, investing, and financing activities. It breaks down various components such as net income, changes in working capital, capital expenditures, and …

Pyxis Oncology Inc (PYXS) Balance Sheet

This article provides a detailed balance sheet for Pyxis Oncology Inc (PYXS), presenting both quarterly and annual financial data. It allows users to assess the company's financial health, examine fundamentals, and calculate key financial ratios related to liquidity, leverage, and return on equity. The …

The Oncology Institute's Q2 results call will stream online Aug. 6

The Oncology Institute (NASDAQ: TOI) announced it will release its second-quarter 2026 financial results on Thursday, August 6, 2026. A conference call will follow on the same day at 5:00 p.m. Eastern Time, accessible via dial-in numbers or a live webcast on the company’s …

Oncology Institute Inc (TOI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Oncology Institute Inc (TOI), listing major individual and institutional holders and their respective proportions. It also provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity, alongside related ETF holdings. Key insights …

CBAN|Colony Bankcorp Inc|Price:21.840|Chg%:+0.320

This article provides a detailed company profile for Colony Bankcorp Inc (CBAN), including its business scope, financial data, and market performance. It outlines the bank's services across three divisions: Banking, Retail Mortgage, and Small Business Specialty Lending, and lists key company information, executives, and …

Oncology Institute Inc (TOI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Oncology Institute Inc (TOI), detailing its business segments for FY2025. Key revenue streams include Dispensary revenue, FFS revenue, Capitated revenue, and Clinical research trials and other revenue, with dispensary revenue forming the largest proportion. The data presented …

Kura Oncology Reports Encouraging Phase 1a Data for Darlifarnib Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma

Kura Oncology announced positive Phase 1a results from its FIT-001 clinical trial for darlifarnib plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). The combination therapy demonstrated response rates up to 50% and a median progression-free survival of 13 months, along …

Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial

Kura Oncology announced positive Phase 1a results for its darlifarnib-cabozantinib combination therapy in advanced clear cell renal cell carcinoma, showing up to a 50% response rate and durable tumor shrinkage. The company is currently enrolling for a randomized Phase 1b study to determine the …

Pyxis Oncology Inc (PYXS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Pyxis Oncology Inc. (PYXS), outlining its major shareholders, investor types, and institutional holdings. It provides a breakdown of proportions held by entities like Pfizer Inc., Laurion Capital Management LP, and various categories such as hedge funds and …

Pyxis Oncology Inc (PYXS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pyxis Oncology Inc's (PYXS) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and offers no dividend data. The article also presents current stock performance data and …

Champions Oncology Inc (CSBR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Champions Oncology Inc (CSBR), outlining major institutional and individual holdings. It lists the top shareholders, the proportion of shares held by different investor types, and historical institutional shareholding data. The data indicates significant holdings by Battery Management …

Octagon Capital Advisors LP Sells 324,110 Shares of BridgeBio Oncology Therapeutics, Inc $BBOT

Octagon Capital Advisors LP has reduced its stake in BridgeBio Oncology Therapeutics (NASDAQ:BBOT) by 31.1%, selling 324,110 shares but still holding 719,000 shares valued at approximately $6.44 million. Despite institutional selling, analysts generally maintain a "Moderate Buy" rating with an average price target of …

2,866,256 Shares in ALX Oncology Holdings Inc. $ALXO Purchased by Orbimed Advisors LLC

Orbimed Advisors LLC purchased 2.87 million shares of ALX Oncology Holdings Inc. ($ALXO) in the first quarter, a stake valued at approximately $5.75 million. This acquisition makes Orbimed Advisors LLC the owner of about 2.13% of ALX Oncology. Other institutional investors collectively hold 97.97% …

Colony Bankcorp Inc Today's Market Trends | CBAN Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

This article provides an in-depth analysis of Colony Bankcorp Inc (CBAN) stock, including real-time quotes, key financial figures, and market trends. It highlights the company's strong fundamentals, high growth potential, and "Buy" rating from analysts, alongside details on its business segments and institutional ownership. …

Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Citius Oncology Inc (CTOR) focusing on its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts or stock splits. The piece presents …

Champions Oncology (NASDAQ:CSBR) Releases Earnings Results, Hits Estimates

Champions Oncology earnings beat by $0.06, revenue topped estimates

Colony Bankcorp: Q2 Earnings Snapshot

This article provides a brief snapshot of Colony Bankcorp's second-quarter earnings. Unfortunately, the content of the article itself is missing, replaced by a privacy message. Therefore, no specific financial details can be extracted from the provided text.

CRDF|Cardiff Oncology Inc|Price:0.827|Chg%:-0.011

This article provides a detailed financial overview of Cardiff Oncology Inc. (CRDF), including its stock performance, key financial indicators, and historical data from income statements, balance sheets, and cash flow statements. It highlights the company's latest earnings report and future forecasts, offering investors comprehensive …

ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a detailed historical overview of ALX Oncology Holdings Inc (ALXO) stock, focusing on dividend payouts and stock splits. It indicates that ALXO has not distributed any dividends over the past five years. The page also presents current stock performance data and …

Champions Oncology Inc (CSBR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Champions Oncology Inc (CSBR) dividend and stock split history, indicating that no dividend data is available for the past five years. It also includes current stock price information and market capitalization for CSBR. The content appears to be …

Champions Oncology Inc (CSBR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a brief overview of Champions Oncology Inc (CSBR), including its stock performance and market cap. It highlights that detailed revenue breakdown data by business segment and region has not yet been disclosed by the company, though it lists United States revenue …

Earnings Beat: Colony Bankcorp, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Colony Bankcorp, Inc. (NYSE:CBAN) exceeded analyst expectations for its latest quarter, reporting revenues of US$42m and statutory EPS of US$0.51. Despite the strong performance, analysts have not significantly altered their forecasts for 2026, maintaining revenue estimates of US$172.1m and EPS of US$1.69, suggesting the …

Colony Bankcorp Inc (CBAN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Colony Bankcorp Inc (CBAN), listing its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdings for key investors. The article also …

BridgeBio Oncology Therapeutics Ord Shs (BBOT) Institutional Confidence

The article provides an overview of institutional confidence in BridgeBio Oncology Therapeutics Ord Shs (BBOT) by listing the top institutional shareholders and their shareholdings. It details the number of shares held by major investment firms such as Cormorant Asset Management, BridgeBio Pharma, and Deerfield …

BridgeBio Oncology Therapeutics Ord Shs (BBOT) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for BridgeBio Oncology Therapeutics Ord Shs (BBOT), highlighting analyst ratings, target price, and expected EPS and revenue growth. Based on 11 analysts, the stock has a "Buy" trend with a significant upside space. The document also includes a …

Granahan Investment Management LLC Buys Shares of 231,040 BridgeBio Oncology Therapeutics, Inc $BBOT

Granahan Investment Management LLC has acquired 231,040 shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) during the first quarter, now holding a 0.29% stake valued at approximately $2.07 million. Other institutional investors have also increased their positions, with hedge funds and institutions collectively owning 54.89% of …

BBOT Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Advances - Tangible Book Value

ALXO Balance Sheet

This article provides a detailed balance sheet analysis for ALX Oncology Holdings Inc (ALXO), presenting quarterly and annual financial data spanning several years for various assets, liabilities, and shareholders' equity categories. It allows users to evaluate the company's financial health and understand key financial …

ALXO|ALX Oncology Holdings Inc|Price:2.030|Chg%:+0.010

ALX Oncology Holdings Inc. (ALXO) is a clinical-stage biotechnology company with a strong growth potential, despite relatively weak fundamentals. The stock is considered fairly valued and has a high institutional ownership. Analysts rate it as a "Buy" with a target price of $4.60, indicating …